4.17
-0.25(-5.66%)
Currency In USD
| Previous Close | 4.42 |
| Open | 4.42 |
| Day High | 4.48 |
| Day Low | 3.95 |
| 52-Week High | 4.6 |
| 52-Week Low | 1 |
| Volume | 1.05M |
| Average Volume | 1.21M |
| Market Cap | 150.06M |
| PE | -2.12 |
| EPS | -1.97 |
| Moving Average 50 Days | 2.21 |
| Moving Average 200 Days | 1.98 |
| Change | -0.25 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $230.81 as of July 14, 2025 at a share price of $4.06. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $537.04 as of July 14, 2025 at a share price of $4.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term extension - - First U.S. patent granted on a deep cyclic inhibitor: a once-daily pill that aims to drive longer-la
Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients
GlobeNewswire Inc.
Jun 17, 2025 10:00 AM GMT
- 94% OS and 72% PFS observed at 6 months for atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-paclitaxel (mGnP), N=34; median OS and PFS not yet reached - - Striking tumor reductions with 39% overall response rate and 81% diseas
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today announced that it will host a conference call and live webc